The Duke Neurogenetics Study (DNS) assesses a wide range of behavioral, experiential, and biological phenotypes among young-adult (aged 18-22) college students (Gorka, Knodt, & Hariri, 2014; Corral-Frías et al., 2015). European-American participants who completed the ongoing DNS for whom overlapping fMRI threat-related amygdala reactivity and genetic data were available as of January 6, 2014, were included in analyses (N = 325). Participants provided informed written consent prior to participation and were in good general health and free of DNS exclusion criteria: (1) medical diagnosis of cancer, stroke, diabetes requiring insulin treatment, chronic kidney or liver disease or lifetime psychotic symptoms; (2) use of psychotropic, glucocorticoid or hypolipidemic medication, and (3) conditions affecting cerebral blood flow and metabolism (e.g., hypertension). Current DSM-IV Axis I and select Axis II disorders (i.e., Antisocial Personality Disorder and Borderline Personality Disorder) were assessed with the electronic Mini International Neuropsychiatric Interview (Sheehan, 1998) and Structured Clinical Interview for the DSM-IV Axis II (SCID-II; First, Gibbon, Spitzer, Williams, & Benjamin, 1997). These disorders are not exclusionary, as the DNS seeks to establish broad variability in multiple behavioral
